Published in Pharmacol Rep on December 29, 2005
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Moderate exercise and chronic stress produce counteractive effects on different areas of the brain by acting through various neurotransmitter receptor subtypes: a hypothesis. Theor Biol Med Model (2006) 1.06
Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci (2013) 0.92
A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health (2007) 0.87
Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism. Neuropsychopharmacology (2014) 0.81
Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. Exp Neurol (2015) 0.77
A Review of Dietary Ziziphus jujuba Fruit (Jujube): Developing Health Food Supplements for Brain Protection. Evid Based Complement Alternat Med (2017) 0.75
Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia (2013) 1.15
Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.97
Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm (Vienna) (2008) 0.94
Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. Eur J Pharmacol (2004) 0.89
Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacol Rep (2010) 0.83
Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep (2008) 0.83
Chronic unpredictable stress-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment. Pharmacol Rep (2011) 0.80
Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep (2006) 0.80
Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol (2005) 0.79
Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol Rep (2009) 0.79
Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol (2004) 0.79
Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Pol J Pharmacol (2003) 0.78
Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther (2006) 0.78
Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep (2009) 0.77
Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test. Pharmacol Rep (2010) 0.77
Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep (2010) 0.76
Effect of repeated co-treatment with imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and alpha 1-adrenergic systems in rats. Pharmacol Rep (2007) 0.76
Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep (2009) 0.76
Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats. Pharmacol Rep (2009) 0.75
Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol (2005) 0.75